{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T13:57:14Z","timestamp":1726235834837},"reference-count":16,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"name":"Aegerion","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharmacology"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1002\/jcph.581","type":"journal-article","created":{"date-parts":[[2015,6,26]],"date-time":"2015-06-26T21:42:33Z","timestamp":1435354953000},"page":"47-55","source":"Crossref","is-referenced-by-count":7,"title":["Evaluation of the effects of the weak CYP3A inhibitors atorvastatin and ethinyl estradiol\/norgestimate on lomitapide pharmacokinetics in healthy subjects"],"prefix":"10.1002","volume":"56","author":[{"given":"Gina","family":"Patel","sequence":"first","affiliation":[{"name":"Covance Early Clinical Biometrics; Madison WI USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"King","sequence":"additional","affiliation":[{"name":"Covance Clinical Research Unit, Inc.; Dallas TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santanu","family":"Dutta","sequence":"additional","affiliation":[{"name":"Covance Early Clinical Biometrics; Madison WI USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Korb","sequence":"additional","affiliation":[{"name":"Covance Early Clinical Biometrics; Madison WI USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet R.","family":"Wade","sequence":"additional","affiliation":[{"name":"SGS Exprimo NV; Mechelen Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Foulds","sequence":"additional","affiliation":[{"name":"Aegerion Pharmaceuticals, Inc.; Cambridge MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Sumeray","sequence":"additional","affiliation":[{"name":"Aegerion Pharmaceuticals, Inc.; Cambridge MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,9,10]]},"reference":[{"issue":"32","key":"10.1002\/jcph.581-BIB0001|jcph581-cit-0001","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur Heart J."},{"issue":"6","key":"10.1002\/jcph.581-BIB0002|jcph581-cit-0002","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/humu.1380010602","article-title":"Molecular genetics of the LDL receptor gene in familial hypercholesterolemia","volume":"1","author":"Hobbs","year":"1992","journal-title":"Hum Mutat."},{"issue":"2","key":"10.1002\/jcph.581-BIB0003|jcph581-cit-0003","doi-asserted-by":"crossref","first-page":"139","DOI":"10.18553\/jmcp.2013.19.2.139","article-title":"Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"19","author":"Robinson","year":"2013","journal-title":"J Manag Care Pharm."},{"key":"10.1002\/jcph.581-BIB0004|jcph581-cit-0004","unstructured":"2014"},{"key":"10.1002\/jcph.581-BIB0005|jcph581-cit-0005","unstructured":"2015"},{"key":"10.1002\/jcph.581-BIB0006|jcph581-cit-0006","doi-asserted-by":"crossref","unstructured":"Davis KA Miyares MA. Am J Health Syst Pharm 2014 71 12 1001 1008","DOI":"10.2146\/ajhp130592"},{"key":"10.1002\/jcph.581-BIB0007|jcph581-cit-0007","unstructured":"Cuchel M Meagher EA Lancet 2013"},{"issue":"3","key":"10.1002\/jcph.581-BIB0008|jcph581-cit-0008","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/phar.1351","article-title":"Pharmacokinetic interactions of the microsomal triglyceride transfer protein inhibitor, lomitapide, with drugs commonly used in the management of hypercholesterolemia","volume":"34","author":"Tuteja","year":"2014","journal-title":"Pharmacotherapy."},{"key":"10.1002\/jcph.581-BIB0009|jcph581-cit-0009","unstructured":"http:\/\/wwwfdagov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/defaulthtm"},{"issue":"7","key":"10.1002\/jcph.581-BIB0010|jcph581-cit-0010","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/bdd.236","article-title":"Dose staggering as a strategy to reduce drug-drug interactions due to reversible enzyme inhibition between orally administered drugs with high first pass effect: a computer simulation study","volume":"21","author":"Fang","year":"2000","journal-title":"Biopharm Drug Dispos."},{"issue":"5","key":"10.1002\/jcph.581-BIB0011|jcph581-cit-0011","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0009-9236(03)00006-7","article-title":"Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors","volume":"73","author":"Washington","year":"2003","journal-title":"Clin Pharmacol Ther."},{"issue":"7","key":"10.1002\/jcph.581-BIB0012|jcph581-cit-0012","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1124\/dmd.113.056309","article-title":"Hepatic uptake of atorvastatin: influence of variability in transporter expression on uptake clearance and drug-drug interactions","volume":"42","author":"Vildhede","year":"2014","journal-title":"Drug Metab Dispos."},{"key":"10.1002\/jcph.581-BIB0013|jcph581-cit-0013","unstructured":"2012"},{"issue":"2","key":"10.1002\/jcph.581-BIB0014|jcph581-cit-0014","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa061189","article-title":"Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia","volume":"356","author":"Cuchel","year":"2007","journal-title":"N Engl J Med."},{"issue":"2","key":"10.1002\/jcph.581-BIB0015|jcph581-cit-0015","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.atherosclerosissup.2014.07.005","article-title":"Clinical experience of lomitapide therapy in patients with homozygous familial hypercholesterolaemia","volume":"15","author":"Cuchel","year":"2014","journal-title":"Atheroscler Suppl."},{"key":"10.1002\/jcph.581-BIB0016|jcph581-cit-0016","unstructured":"Desai CS Martin SS BMJ 2014"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcph.581","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/jcph.581","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T12:56:03Z","timestamp":1657803363000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jcph.581"}},"subtitle":["Evaluation of the Effects of the Weak CYP3A"],"short-title":[],"issued":{"date-parts":[[2015,9,10]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jcph.581","archive":["Portico"],"relation":{},"ISSN":["0091-2700"],"issn-type":[{"value":"0091-2700","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9,10]]}}}